NOT-AI-26-002: Notice of NIAID Participation in RFA-HL-26-017, Catalyze: Product Definition for Small Molecules, Biologics and Combination Products-Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33)

Notice of NIAID Participation in RFA-HL-26-017, Catalyze: Product Definition for Small Molecules, Biologics and Combination Products-Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33)

Notice Number:

NOT-AI-26-002

Key Dates

Release Date:

April 28, 2026

Related Announcements

November 22, 2024 - Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed). See NOFO RFA-HL-26-017.

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

This Notice informs potential applicants that the National Institute of Allergy and Infectious Diseases (NIAID) is participating, effective for due dates on or after June 18, 2026, in the Notice of Funding Opportunity Announcement (NOFO) RFA-HL-26-017, "Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)".

The following sections of RFA-HL-26-017 have been modified (changes shown in bold italics) to reflect NIAID's participation in this NOFO:

Part 1. Overview Information

Components of Participating Organizations

National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Allergy and Infectious Diseases (NIAID)

Assistance Listing Number(s)

93.837, 93.233, 93.838, 93.839; 93.855

Section VII. Agency Contacts

Scientific/Research Contact(s)
General Questions
Mike Pieck, Ph.D.
Telephone: 301-827-7986
Email: [email protected]

Division of Blood Diseases and Research
Crystal Hill-Pryor, Ph.D., MPH
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-443-9337
Email: [email protected]

Division of Cardiovascular Sciences
Simhan Danthi, Ph.D.
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-451-5170
Email: [email protected]

National Center on Sleep Disorders Research
Alfonso Alfini, Ph.D.
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-435-0199
Email: [email protected]

Division of Lung Diseases
Qing Lu, Ph.D.
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-480-9158
Email:[email protected]

Chemical Countermeasures Research Program (CCRP)
National Institute of Allergy and Infectious Diseases (NIAID)
Email: [email protected]

Financial/Grants Management Contact(s)
Ron Caulder
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-8020
Email: [email protected]

National Institute of Allergy and Infectious Diseases (NIAID)
Email: [email protected]

All other aspects of the NOFO remain the same.

Inquiries

Please direct all inquiries to:

Catalyze Program
National Heart, Lung and Blood Institute (NHLBI)
Email: [email protected]

Chemical Countermeasures Research Program (CCRP)
National Institute of Allergy and Infectious Diseases (NIAID)
Email: [email protected]